Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928914 · ClinicalTrials.gov registry record · Phase 1
Tafenoquine Thorough QTc Study in Healthy Subjects
A Phase 1 study of Malaria, Vivax, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 2
- Study locations
NCT01928914 is a Phase 1 study of Malaria, Vivax that has completed, run by GlaxoSmithKline. The registered enrollment target is 260 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01928914, a Phase 1 study of Malaria, Vivax, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 2
- Study locations
Study Summary
This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups. This study is designed to compare the effects of tafenoquine, administered as single dose as well as administered over three consecutive days, on the changes in QT duration to those observed in subjects dosed with either moxifloxacin or placebo.
Conditions Studied
Interventions
- DRUG moxifloxacin
- DRUG Tafenoquine 300mg
- DRUG Tafenoquine 600mg
- DRUG Tafenoquine 1200mg
- DRUG Placebo for Tafenoquine
Study Locations (2)
California
- GSK Investigational Site - Culver City
Maryland
- GSK Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2011-07-26 |
| Est. Completion | 2012-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928914
The ClinicalTrials.gov registry entry for NCT01928914 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria, Vivax appearing as the primary indexed condition, and to 5 interventions - of which moxifloxacin is the first listed.
NCT01928914 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT01928914 about?
NCT01928914 is a clinical study titled "Tafenoquine Thorough QTc Study in Healthy Subjects". This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups. This study is designed to compare the effects of tafenoquine, administered as single dose as well as administered over three consecutive days, on the changes...
What is the current status of trial NCT01928914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2011-07-26. Estimated completion is 2012-06-04.
What conditions does trial NCT01928914 study?
This clinical trial studies the following conditions: Malaria, Vivax.
What interventions are being tested in trial NCT01928914?
The interventions under investigation include: moxifloxacin (DRUG), Tafenoquine 300mg (DRUG), Tafenoquine 600mg (DRUG), Tafenoquine 1200mg (DRUG), Placebo for Tafenoquine (DRUG).
Who is sponsoring clinical trial NCT01928914?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01928914 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.